hVIVO has noted and congratulated its client Cidara Therapeutics, which has entered into an agreement under which Merck Sharp & Dohme (MSD) will acquire Cidara for c$9.2bn. hVIVO partnered with Cidara throughout the development of its lead candidate CD388 – a long-acting, strain-agnostic antiviral agent designed to prevent influenza infection – and continues to support Cidara through Phase III development, acting as a major clinical site for the ongoing multi-site trial. hVIVO has also acted as ....
